Expression of membrane drug efflux transporters in the sigmoid colon of hiv-infected and uninfected men

Journal of Clinical Pharmacology

Volumn 53, Issue 9, 2013, Pages 934-945

  De Rosa, María Fabiana ^a   Robillard, Kevin R ^a   Kim, Connie J ^b   Hoque, Md Tozammel ^a   Kandel, Gabor ^c   Kovacs, Colin ^d   Kaul, Rupert ^b,e   Bendayan, Reina ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d MAPLE LEAF MEDICAL CLINIC   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Antiretroviral therapy; Drug efflux transporters; HIV; Pre exposure prophylaxis; Sigmoid colon

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BREAST CANCER RESISTANCE PROTEIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLON BIOPSY; CONTROLLED STUDY; DRUG PENETRATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; MALE; PROTEIN EXPRESSION; SIGMOID;

ANTIRETROVIRAL THERAPY; DRUG EFFLUX TRANSPORTERS; HIV; PRE-EXPOSURE PROPHYLAXIS; SIGMOID COLON;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COLON, SIGMOID; HIV INFECTIONS; HUMANS; LYMPHOCYTE COUNT; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; RNA, MESSENGER; VIRAL LOAD; YOUNG ADULT;

EID: 84885085309     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.132     Document Type: Article

References (47)

1. UNAIDS. Report on the global AIDS epidemic 2010. UNAIDS; December 2010. 2011.
2. Klasse PJ, Shattock R, Moore JP. Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu Rev Med. 2008;59:455-471. (Pubitemid 351287949)
3. Cohen MS, Gay C, Kashuba AD, Blower S, Paxton L. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med. 2007;146(8):591-601. (Pubitemid 351650540)
4. Tsai CC, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science. 1995;270(5239):1197-1199.
5. Abdool Karim Q, Karim Abdool SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329 (5996):1168-1174.
6. Walker DK, Abel S, Comby P, Muirhead GJ, Nedderman AN, Smith DA. Species differences in the disposition of the CCR5 antagonist, UK-427, 857, a new potential treatment for HIV. Drug Metab Dispos. 2005;33(4):587-595. (Pubitemid 40393203)
7. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.N Engl J Med. 2010;363(27):2587- 2599.
8. Brown KC, Paul S, Kashuba AD. Drug interactions with new and investigational antiretrovirals. Clin Pharmacokinet. 2009;48 (4):211-241.
9. Kis O, Robillard K, Chan GN, Bendayan R. The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharmacol Sci. 2010;31(1):22-35.
10. Weiss J, Haefeli WE. Impact of ATP-binding cassette transporters on human immunodeficiency virus therapy. Int Rev Cell Mol Biol. 2010;280:219-279.
11. Kis O, Zastre JA, Hoque MT, Walmsley SL, Bendayan R. Role of drug efflux and uptake transporters in atazanavir intestinal permeability and drug-drug interactions. Pharm Res. 2013;30 (4):1050-1064.
12. Zimmermann C, Gutmann H, Hruz P, Gutzwiller JP, Beglinger C, Drewe J. Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract. Drug Metab Dispos. 33(2):219-224.
13. Takano M, Yumoto R, Murakami T. Expression and function of efflux drug transporters in the intestine. Pharmacol Ther. 2006;109 (1-2):137-161. (Pubitemid 41740818)
14. Imaoka T, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y. Functional involvement of multidrug resistanceassociated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol. 2007;71 (2):619-627. (Pubitemid 46147926)
15. Mallants R, Van Oosterwyck K, Van Vaeck L, Mols R, De Clercq E, Augustijns P. Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites. Xenobiotica. 2005;35(10-11):1055-1066. (Pubitemid 43068047)
16. Gutmann H, Hruz P, Zimmermann C, Beglinger C, Drewe J. Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract. Biochem Pharmacol. 2005;70(5):695-699. (Pubitemid 41058704)
17. Ufer M, Hasler R, Jacobs G, et al. Decreased sigmoidal ABCB1 (Pglycoprotein) expression in ulcerative colitis is associated with disease activity. Pharmacogenomics. 2009;10(12):1941-1953.
18. Sheth PM, Chege D, Shin LY, et al. Immune reconstitution in the sigmoid colon after long-term HIV therapy. Mucosal Immunol. 2008;1(5):382-388.
19. Chan GN, Hoque MT, Cummins CL, Bendayan R. Regulation of Pglycoprotein by orphan nuclear receptors in human brain microvessel endothelial cells. J Neurochem. 2011;118(2):163-175.
20. Ronaldson PT, Bendayan R. HIV-1 viral envelope glycoprotein gp120 triggers an inflammatory response in cultured rat astrocytes and regulates the functional expression of P-glycoprotein. Mol Pharmacol. 2006;70(3):1087-1098. (Pubitemid 44268466)
21. Ronaldson PT, Ashraf T, Bendayan R. Regulation of multidrug resistance protein 1 by tumor necrosis factor alpha in cultured glial cells: involvement of nuclear factor-kappaB and c-Jun N-terminal kinase signaling pathways. Mol Pharmacol. 2010;77(4):644-659.
22. Zastre JA, Chan GN, Ronaldson PT, et al. Up-regulation of Pglycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line. J Neurosci Res. 2009;87(4):1023-1036.
23. Bookout AL, Cummins CL, Mangelsdorf DJ, Pesola JM, Kramer MF. High-throughput real-time quantitative reverse transcription PCR. Current protocols in molecular biology/edited by FrederickM. Ausubel ... [et al.] 2006; Chapter 15: Unit 15 18.
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-408. (Pubitemid 34164012)
25. Dussault I, Lin M, Hollister K, Wang EH, Synold TW, Forman BM. Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J Biol Chem. 2001;276(36):33309-33312.
26. Poles MA, Elliott J, Taing P, Anton PA, Chen IS. A preponderance of CCR5() CXCR4() mononuclear cells enhances gastrointestinal mucosal susceptibility to human immunodeficiency virus type 1 infection. J Virol. 2001;75(18):8390-8399. (Pubitemid 32768943)
27. Pereira LH, Embil JA, Haase DA, Manley KM. Prevalence of human immunodeficiency virus in the patient population of a sexually transmitted disease clinic. Association with syphilis and gonorrhea. Sex Transm Dis. 1992;19(2):115-120. (Pubitemid 23101894)
28. Wijnholds J, Mol CA, van Deemter L, et al. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. ProcNatlAcadSciUSA. 2000;97(13):7476-7481. (Pubitemid 30431488)
29. Weiss J, Theile D, Ketabi-Kiyanvash N, Lindenmaier H, Haefeli WE. Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab Dispos. 2007;35(3):340-344. (Pubitemid 46333919)
30. Ashraf T, Ronaldson PT, Persidsky Y, Bendayan R. Regulation of P-glycoprotein by human immunodeficiency virus-1 in primary cultures of human fetal astrocytes. J Neurosci Res. 2011;89 (11):1773-1782.
31. Chen Y, Tang Y, Guo C, Wang J, Boral D, Nie D. Nuclear receptors in the multidrug resistance through the regulation of drugmetabolizing enzymes and drug transporters. Biochem Pharmacol. 2012;83(8):1112-1126.
32. Meaden ER, Hoggard PG, Maher B, Khoo SH, Back DJ. Expression of P-glycoprotein and multidrug resistance-associated protein in healthy volunteers and HIV-infected patients. AIDS Res Hum Retroviruses. 2001;17(14):1329-1332. (Pubitemid 33042758)
33. Blokzijl H, Vander Borght S, Bok LI, et al. Decreased Pglycoprotein (P-gp/MDR1) expression in inflamed human intestinal epithelium is independent of PXR protein levels. Inflamm Bowel Dis. 2007;13(6):710-720. (Pubitemid 46909985)
34. Chandler B, Almond L, Ford J, et al. The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on Pglycoprotein expression in peripheral blood mononuclear cells in vitro. J Acquir Immune Defic Syndr. 2003;33(5):551-556. (Pubitemid 36975841)
35. Perloff MD, von Moltke LL, Greenblatt DJ. Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats. Xenobiotica. 2004;34(2):133-150. (Pubitemid 38299715)
36. Perloff MD, von Moltke LL, Fahey JM, Daily JP, Greenblatt DJ. Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. Aids. 2000;14(9):1287-1289. (Pubitemid 30420680)
37. Vishnuvardhan D, Moltke LL, Richert C, Greenblatt DJ. Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. Aids. 2003;17(7):1092-1094. (Pubitemid 36549726)
38. Burk O, Koch I, Raucy J, et al. The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J Biol Chem. 2004;279(37):38379- 38385. (Pubitemid 39295987)
39. Tolson AH, Wang H. Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. Adv Drug Deliv Rev. 2010;62 (13):1238-1249.
40. Raynal C, Pascussi JM, Leguelinel G, et al. Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation. Mol Cancer. 2010;9:46.
41. Langmann T, Moehle C, Mauerer R, et al. Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology. 2004;127(1):26-40. (Pubitemid 38962271)
42. Courtois A, Payen L, Guillouzo A, Fardel O. Up-regulation of multidrug resistance-associated protein 2 (MRP2) expression in rat hepatocytes by dexamethasone. FEBS Lett. 1999;459(3):381-385. (Pubitemid 29467372)
43. Fromm MF, Kauffmann HM, Fritz P, et al. The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol. 2000;157(5):1575-1580.
44. Kast HR, Goodwin B, Tarr PT, et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem. 2002;277(4):2908-2915. (Pubitemid 34953324)
45. Ohtsuki S, Schaefer O, Kawakami H, et al. Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDPglucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab Dispos. 2012;40(1):83-92.
46. Gomez-Martinez A, Garcia-Morales P, Carrato A, et al. Posttranscriptional regulation of P-glycoprotein expression in cancer cell lines. Mol Cancer Res. 2007;5(6):641-653. (Pubitemid 46985052)
47. Reid G, Wielinga P, Zelcer N, et al. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol. 2003;63(5):1094-1103. (Pubitemid 36529928)